ZA97657B - Ligand directed enzyme prodrug therapy. - Google Patents

Ligand directed enzyme prodrug therapy.

Info

Publication number
ZA97657B
ZA97657B ZA9700657A ZA97657A ZA97657B ZA 97657 B ZA97657 B ZA 97657B ZA 9700657 A ZA9700657 A ZA 9700657A ZA 97657 A ZA97657 A ZA 97657A ZA 97657 B ZA97657 B ZA 97657B
Authority
ZA
South Africa
Prior art keywords
prodrug therapy
directed enzyme
enzyme prodrug
ligand directed
ligand
Prior art date
Application number
ZA9700657A
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of ZA97657B publication Critical patent/ZA97657B/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA9700657A 1996-01-26 1997-01-27 Ligand directed enzyme prodrug therapy. ZA97657B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9601640.7A GB9601640D0 (en) 1996-01-26 1996-01-26 Ligand directed enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
ZA97657B true ZA97657B (en) 1997-08-01

Family

ID=10787646

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9700657A ZA97657B (en) 1996-01-26 1997-01-27 Ligand directed enzyme prodrug therapy.

Country Status (9)

Country Link
EP (1) EP0876160B1 (de)
JP (1) JP2000504218A (de)
AT (1) ATE187890T1 (de)
AU (1) AU709238B2 (de)
DE (1) DE69700983D1 (de)
GB (1) GB9601640D0 (de)
NZ (1) NZ326436A (de)
WO (1) WO1997026918A2 (de)
ZA (1) ZA97657B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CN1357048A (zh) * 1998-03-06 2002-07-03 牛津生物医学(英国)有限公司 增强前体药物活化
ES2313779T3 (es) * 1998-03-13 2009-03-01 The Burnham Institute Moleculas que migran a diversos organos o tejidos seleccionados.
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US10947270B2 (en) * 2015-08-27 2021-03-16 National Yang-Ming University Targeted prodrug cytosine deaminase fusion carrier and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
ATE361759T1 (de) * 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ,インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
WO1996021416A2 (en) * 1994-12-30 1996-07-18 Chiron Corporation Methods and compositions for treatment of solid tumors in vivo

Also Published As

Publication number Publication date
ATE187890T1 (de) 2000-01-15
EP0876160B1 (de) 1999-12-22
EP0876160A2 (de) 1998-11-11
DE69700983D1 (de) 2000-01-27
WO1997026918A3 (en) 1997-10-23
JP2000504218A (ja) 2000-04-11
AU1453097A (en) 1997-08-20
NZ326436A (en) 1999-03-29
AU709238B2 (en) 1999-08-26
WO1997026918A2 (en) 1997-07-31
GB9601640D0 (en) 1996-03-27

Similar Documents

Publication Publication Date Title
WO1996003515A3 (en) Surface expression of enzyme in gene directed prodrug therapy
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
TNSN97009A1 (fr) 2-oxo- et 2-thio- 1,2- dihydroquinoleinyl-oxazolidinones.
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
ZA97657B (en) Ligand directed enzyme prodrug therapy.
WO2001061017A3 (en) Modified cytokines for use in cancer therapy
MY137303A (en) Methods for treating proliferative diseases
AU8239298A (en) Nucleotide-comprising composition
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
AU2356001A (en) Surface treatment agent for laminated fabric
WO1999064065A3 (en) Tumour therapy and imaging
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
GB9723824D0 (en) Cytostatic agents
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
ES2141044A1 (es) Terapia con oxibutinina.
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
AU5969500A (en) 10-formyltetrahydrofolate dehydrogenase as therapeutical agent
EP1800664B8 (de) Pharmazeutische Zubereitungen zur parenteralen Verabreichung enthaltend Epothilon
MX9701031A (es) Utilizacion de la selegilina para el tratamiento de enfermedades epilepticas.
AU2143597A (en) The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias